studies

mHCC - 1st line (L1), ... vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 459, 2019 (REV) 1.18 [0.99; 1.40] IMbrave-150, 2020 (REV) 1.72 [1.26; 2.36] 1.39[0.96; 2.02]CheckMate 459, 2019 (REV), IMbrave-150, 2020 (REV)277%1,244moderatenot evaluable progression or deaths (PFS)detailed resultsCheckMate 459, 2019 (REV) 1.08 [0.91; 1.27] IMbrave-150, 2020 (REV) 1.69 [1.33; 2.16] 1.34[0.86; 2.09]CheckMate 459, 2019 (REV), IMbrave-150, 2020 (REV)289%1,244moderatenot evaluable objective responses (ORR)detailed resultsCheckMate 459, 2019 (REV) 0.41 [0.25; 0.67] IMbrave-150, 2020 (REV) 0.36 [0.21; 0.62] 0.39[0.27; 0.56]CheckMate 459, 2019 (REV), IMbrave-150, 2020 (REV)20%1,244moderatenot evaluable AE (any grade)detailed resultsIMbrave-150, 2020 (REV) 1.43 [0.29; 7.17] 1.43[0.29; 7.17]IMbrave-150, 2020 (REV)10%485NAnot evaluable AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 0.94 [0.64; 1.39] 0.94[0.64; 1.39]IMbrave-150, 2020 (REV)10%485NAnot evaluable AE leading to death (grade 5)detailed resultsIMbrave-150, 2020 (REV) 1.28 [0.55; 3.00] 1.28[0.55; 3.00]IMbrave-150, 2020 (REV)10%485NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMbrave-150, 2020 (REV) 0.62 [0.34; 1.13] 0.62[0.34; 1.13]IMbrave-150, 2020 (REV)10%485NAnot evaluable SAE (any grade)detailed resultsIMbrave-150, 2020 (REV) 0.73 [0.48; 1.09] 0.73[0.48; 1.09]IMbrave-150, 2020 (REV)10%485NAnot evaluable STRAE (grade 3-4)detailed resultsCheckMate 459, 2019 (REV) 3.32 [2.41; 4.57] 3.32[2.41; 4.57]CheckMate 459, 2019 (REV)10%743NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 459, 2019 (REV) 1.88 [1.00; 3.52] 1.88[1.00; 3.52]CheckMate 459, 2019 (REV)10%743NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 2.14 [0.53; 8.66] 2.14[0.53; 8.66]IMbrave-150, 2020 (REV)10%485NAnot evaluable Acute kidney injury AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 6.43 [0.66; 62.33] 6.43[0.66; 62.33]IMbrave-150, 2020 (REV)10%485NAnot evaluable Alopecia AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 2.11 [0.04; 106.97] 2.11[0.04; 106.97]IMbrave-150, 2020 (REV)10%485NAnot evaluable Anaemia AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 0.94 [0.28; 3.09] 0.94[0.28; 3.09]IMbrave-150, 2020 (REV)10%485NAnot evaluable Asthenia AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 8.63 [0.96; 77.88] 8.63[0.96; 77.88]IMbrave-150, 2020 (REV)10%485NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 2.11 [0.04; 106.97] 2.11[0.04; 106.97]IMbrave-150, 2020 (REV)10%485NAnot evaluable Cough AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 4.24 [0.14; 127.03] 4.24[0.14; 127.03]IMbrave-150, 2020 (REV)10%485NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 3.25 [0.90; 11.69] 3.25[0.90; 11.69]IMbrave-150, 2020 (REV)10%485NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 2.91 [0.99; 8.54] 2.91[0.99; 8.54]IMbrave-150, 2020 (REV)10%485NAnot evaluable Dyspepsia AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 8.53 [0.38; 190.34] 8.53[0.38; 190.34]IMbrave-150, 2020 (REV)10%485NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 1.59 [0.35; 7.21] 1.59[0.35; 7.21]IMbrave-150, 2020 (REV)10%485NAnot evaluable Epistaxis AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 4.24 [0.14; 127.03] 4.24[0.14; 127.03]IMbrave-150, 2020 (REV)10%485NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 1.33 [0.43; 4.13] 1.33[0.43; 4.13]IMbrave-150, 2020 (REV)10%485NAnot evaluable Hypertension AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 0.77 [0.44; 1.36] 0.77[0.44; 1.36]IMbrave-150, 2020 (REV)10%485NAnot evaluable Increase AST AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 0.72 [0.31; 1.65] 0.72[0.31; 1.65]IMbrave-150, 2020 (REV)10%485NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 0.34 [0.08; 1.55] 0.34[0.08; 1.55]IMbrave-150, 2020 (REV)10%485NAnot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 0.13 [0.01; 2.26] 0.13[0.01; 2.26]IMbrave-150, 2020 (REV)10%485NAnot evaluable Nausea AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 2.12 [0.13; 34.06] 2.12[0.13; 34.06]IMbrave-150, 2020 (REV)10%485NAnot evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 59.73 [3.52; 1013.60] 59.73[3.52; 1013.60]IMbrave-150, 2020 (REV)10%485NAnot evaluable Proteinuria AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 0.21 [0.03; 1.62] 0.21[0.03; 1.62]IMbrave-150, 2020 (REV)10%485NAnot evaluable Pruritus AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 2.11 [0.04; 106.97] 2.11[0.04; 106.97]IMbrave-150, 2020 (REV)10%485NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 1.06 [0.19; 5.82] 1.06[0.19; 5.82]IMbrave-150, 2020 (REV)10%485NAnot evaluable Rash AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 17.29 [0.91; 329.11] 17.29[0.91; 329.11]IMbrave-150, 2020 (REV)10%485NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 1.06 [0.26; 4.28] 1.06[0.26; 4.28]IMbrave-150, 2020 (REV)10%485NAnot evaluable Vomiting AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 1.05 [0.09; 11.72] 1.05[0.09; 11.72]IMbrave-150, 2020 (REV)10%485NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsIMbrave-150, 2020 (REV) 4.24 [0.14; 127.03] 4.24[0.14; 127.03]IMbrave-150, 2020 (REV)10%485NAnot evaluable0.0100.01.0relative treatment effectwww.metaEvidence.org2024-07-03 16:00 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 131 - treatments: 670

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons